Ventricular Tachycardia Ablation vs. ENhanced Drug Therapy In Structural Heart Disease - VANISH study

The Queen Elizabeth II Health Sciences Centre0 个研究点目标入组 50 人开始时间: 待定最近更新: 2024年5月6日

适应症

试验速览

暂无简介。

•1. Prior myocardial infarction (pathological Q waves or imaging evidence of regional myocardial akinesis/thinning in the absence of a non-ischemic cause)73
•2. An implantable defibrillator
•3. One of the following VT events (within last 3 months):
•A: *3 episodes of symptomatic VT treated with antitachycardia pacing (ATP),
•B: *1 appropriate ICD shocks,
•C: *3 VT episodes within 24 hr
•D: sustained VT below detection rate of the ICD documented by ECG/cardiac monitor
•4. *Failed* first-line antiarrhythmic drug therapy (Class 1 or 3) as defined by one of:
•A: Appropriate ICD therapy or sustained VT occurred while the patient was taking amiodarone (patient on a stable dose for * 2 weeks)
•B: Appropriate ICD therapy or sustained VT occurred on another antiarrhythmic drug (patient on a stable dose for * 2 weeks)

•1. Are unable or unwilling to provide informed consent.
•2. Have an acute coronary syndrome (acute thrombus diagnosed by coronary angiography, or dynamic ST segment changes demonstrated on ECG) or another reversible cause of VT (e.g. electrolyte abnormalities, drug-induced arrhythmia)
•3. Are known to be ineligible to take amiodarone, e.g. active hepatitis, current hyperthyroidism, pulmonary fibrosis, known allergy.
•4. Are ineligible for ablation (known to have protruding left ventricular thrombus, or have implanted mechanical aortic and mitral valves)
•5. Are in renal failure (Creatinine clearance <15 ml/min)
•6. Have current NYHA Functional class IV heart failure or CCS Functional class IV angina
•7. Had recent ST elevation myocardial infarction (< 1 month)
•8. Had recent coronary bypass surgery (< 3 months) or percutaneous coronary intervention (<1 month)
•9. Are pregnant
•10. Have had prior ablation for ventricular tachycardia
•11. Have a systemic illness likely to limit survival to < 1 year.

发起方

The Queen Elizabeth II Health Sciences Centre